I

    Insmed Inc (INSM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $121.82
    +3.28 (+2.77%)

    Market Cap: $25.89B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    33%(13/40)
    Avg Surprise
    -9.37%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.36
    Range$-0.90 - $0.04
    16 analysts
    EPS Revisions
    7
    0
    7d
    8
    0
    30d
    EPS Estimate Drift
    90d ago$-0.60-65.6%
    60d ago$-0.60-66.1%
    30d ago$-0.63-74.0%
    7d ago$-0.59-63.9%
    Current$-0.36
    Revenue Consensus
    $501M
    Range$457M - $524M
    19 analysts
    Dec 31, 2026
    EPS Consensus$0.49
    Range$-0.61 - $1.61
    17 analysts
    Revenue Consensus
    $611M
    Range$466M - $692M
    21 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.49---
    Sep 26EST
    		-$-0.36---
    Jun 26
    		$-0.52$-0.69+24.64%Beat+69.4%
    Mar 26
    		$-0.76$-1.00+24.00%Beat+46.5%
    Dec 25
    		$-1.54$-1.17-31.62%Miss-16.7%
    Sep 25
    		$-1.75$-1.37-27.74%Miss-37.8%
    Jun 25
    		$-1.70$-1.30-30.77%Miss+12.4%
    Mar 25
    		$-1.42$-1.20-18.33%Miss-34.0%
    Dec 24
    		$-1.32$-1.23-7.32%Miss-3.1%
    Sep 24
    		$-1.27$-1.22-4.10%Miss-14.4%
    Jun 24
    		$-1.94$-1.23-57.72%Miss-9.0%
    Mar 24
    		$-1.06$-1.20+11.67%Beat+9.4%
    Dec 23
    		$-1.28$-1.13-13.27%Miss-5.8%
    Sep 23
    		$-1.11$-1.11+0.00%Beat-1.8%
    Jun 23
    		$-1.78$-1.12-58.93%Miss-122.5%
    Mar 23
    		$-1.17$-1.10-6.36%Miss-46.2%
    Dec 22
    		$-1.21$-1.04-16.35%Miss-27.4%
    Sep 22
    		$-1.09$-0.87-25.29%Miss-13.5%
    Jun 22
    		$-0.80$-0.89+10.11%Beat+12.1%
    Mar 22
    		$-0.80$-0.87+8.05%Beat+10.1%
    Dec 21
    		$-0.95$-0.86-10.47%Miss+5.0%
    Sep 21
    		$-0.96$-0.78-23.08%Miss-52.4%
    Jun 21
    		$-0.91$-0.88-3.41%Miss-42.2%
    Mar 21
    		$-0.89$-0.96+7.29%Beat-20.3%
    Dec 20
    		$-1.00$-0.70-42.86%Miss-69.5%
    Sep 20
    		$-0.63$-0.59-6.78%Miss+7.4%
    Jun 20
    		$-0.64$-0.62-3.23%Miss+21.0%
    Mar 20
    		$-0.74$-0.72-2.78%Miss+22.9%
    Dec 19
    		$-0.59$-0.58-1.72%Miss+50.4%
    Sep 19
    		$-0.68$-0.67-1.49%Miss+40.4%
    Jun 19
    		$-0.81$-0.86+5.81%Beat+19.0%
    Mar 19
    		$-0.96$-1.00+4.00%Beat-10.3%
    Dec 18
    		$-1.19$-1.05-13.33%Miss-40.0%
    Sep 18
    		$-1.14$-1.06-7.55%Miss-65.2%
    Jun 18
    		$-1.00$-1.06+5.66%Beat-38.9%
    Mar 18
    		$-0.87$-0.96+9.38%Beat-45.0%
    Dec 17
    		$-0.85$-0.64-32.81%Miss+22.7%
    Sep 17
    		$-0.69$-0.70+1.43%Beat-13.1%
    Jun 17
    		$-0.72$-0.63-14.29%Miss-
    Mar 17
    		$-0.60$-0.60+0.00%Beat-
    Dec 16
    		$-1.10$-0.89-23.60%Miss-
    Sep 16
    		$-0.61$-0.60-1.67%Miss-

    Key Metrics

    Valuation
    P/E Ratio-26.66EV/EBITDA-6.05x
    Price/FCF-32.78xFCF Yield-3.05%
    Profitability
    Profit Margin-76.90%Operating Margin-23.80%
    ROE-87.20%ROIC-64.90%
    Financial Health
    Debt/Equity0.72xInterest Coverage-16.81x
    Current Ratio3.72xQuick Ratio3.40x
    Trading Statistics
    Beta0.79Avg Volume2.89M
    52-Week High$212.7552-Week Low$90.39

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$124.40
    SMA 20$124.17
    SMA 50$113.84
    SMA 200$142.19
    EMA 10$122.96
    EMA 20$121.56
    EMA 50$117.55
    EMA 200$126.99

    MACD

    Line: 2.66Signal: 3.95Hist: -1.30

    ADX

    ADX: 24.0+DI: 25.4-DI: 21.6

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down20.0
    PSAR$108.42

    Bollinger Bands

    Upper Band$143.51
    Lower Band$104.83
    %B Position3115%(Upper)
    Band Width0.44

    RSI (14-Day)

    Neutral
    52.4

    Momentum Oscillators

    Stoch %K11.6
    Stoch %D10.6
    Williams %R-74.2
    ROC (10d)-5.1%
    Momentum-6.50
    CCI (20d)-38.9
    MFI (14d)38.2

    Volatility Measures

    ATR (14d)$5.02(4.1%)
    StdDev (20d)9.67
    Hist Vol126.4%(High)

    Volume Flow

    VWAP$120.72
    OBV64.8M
    AD Line70.9M
    CMF (20d)-0.040

    Volume Metrics

    Avg Vol (20d)2.9M
    Vol Ratio0.8x
    VWMA (20d)$123.95

    Pivot Points

    R3$123.93
    R2$122.29
    R1$120.42
    Pivot Point$118.78
    S1$116.91
    S2$115.27
    S3$113.40

    Advanced Oscillators

    TSI13.37
    Ultimate Osc43.2
    KST147.05

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$425.49M$305.96M$263.84M$142.34M$107.42M$92.82M$104.44M$93.42M$90.34M$75.50M$83.69M$79.07M
    Cost of Revenue$67.21M$47.42M$44.22M$29.36M$28.07M$21.28M$26.15M$21.17M$20.96M$17.46M$18.44M$16.71M
    Gross Profit$358.27M$258.54M$219.62M$112.98M$79.34M$71.55M$78.29M$72.25M$69.38M$58.04M$65.25M$62.37M
    Operating Expenses$359.82M$411.86M$539.37M$478.98M$392.22M$319.69M$308.70M$285.68M$358.28M$203.55M$243.52M$210.03M
    R&D$210.03M$209.49M$254.91M$186.41M$177.19M$152.58M$179.73M$150.81M$146.75M$121.08M$137.03M$109.15M
    SG&A$247.47M$247.26M$212.48M$186.38M$154.76M$147.54M$142.51M$118.93M$106.57M$93.10M$89.53M$90.63M
    Operating Income$-1,548,000$-153,320,000$-319,748,000$-366,005,000$-312,876,000$-248,140,000$-230,414,000$-213,429,000$-288,904,000$-145,505,000$-178,272,000$-147,668,000
    Interest Income$10.98M$12.04M$0$0$13.22M$13.91M$17.26M$16.98M$10.29M$8.78M$9.85M$10.58M
    Interest Expense$20.27M$20.08M$7.19M$2.70M$21.25M$21.57M$21.55M$21.05M$21.27M$21.04M$20.78M$20.29M
    Income Before Tax$-11,373,000$-162,098,000$-326,934,000$-368,701,000$-320,443,000$-255,671,000$-234,282,000$-219,510,000$-299,771,000$-156,502,000$-185,063,000$-158,389,000
    Income Tax Expense$1.87M$1.47M$1.55M$1.32M$1.24M$912,000$1.27M$1.01M$838,000$589,000$998,000$544,000
    Net Income$-13,242,000$-163,563,000$-328,485,000$-370,021,000$-321,686,000$-256,583,000$-235,548,000$-220,524,000$-300,609,000$-157,091,000$-186,061,000$-158,933,000
    EBITDA$5.29M$-146,981,000$-313,956,000$-360,592,000$-306,322,000$-242,362,000$-224,822,000$-210,553,000$-283,612,000$-138,863,000$-170,614,000$-142,109,000
    EBIT$-2,079,000$-154,056,000$-321,571,000$-366,608,000$-312,423,000$-248,008,000$-229,989,000$-215,438,000$-288,789,000$-144,243,000$-175,782,000$-147,383,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about INSM

    Government Contracts

    Gov Obligations (TTM)
    -$29404
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    2
    New Awards (TTM)
    1
    Avg Remaining Term
    N/A

    Recent Awards

    Award IDAgencyObligatedStart
    36C24526N0641Department of Veterans AffairsDepartment of Veterans Affairs$31229Jun 10, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Insmed director Melvin Sharoky sells $637,650 in shares

    Insmed director Melvin Sharoky indirectly sold 5,000 shares of the company's common stock for $637,650 on August 17, 2026, through Padonia, LLC. Despite the sale occurring near recent highs, Wall Street analysts maintain optimistic price targets for INSMED, which has seen significant revenue growth and strong performance from its lung-disease drugs. The company recently raised its full-year revenue guidance for BRINSUPRI and received regulatory approval in Japan for the drug.

    Investing.com•8/26/26•
    Bullish

    Mizuho raises Insmed stock price target to $195 on Japan approval

    Mizuho increased its price target for Insmed shares to $195 from $192, maintaining an Outperform rating after Japan approved Brinsupri for non-cystic fibrosis bronchiectasis. This approval led Mizuho to raise its probability-of-success assumption for Brinsupri in Japan to 100%. The firm believes the recent share weakness is unwarranted given strong company fundamentals and Brinsupri's launch success, also highlighted by a recent significant revenue beat for the drug.

    Investing.com•8/24/26•
    Bullish

    Insmed receives Japan approval for BRINSUPRI bronchiectasis treatment

    Insmed has received approval from Japan’s Ministry of Health, Labour and Welfare for BRINSUPRI (brensocatib) to treat non-cystic fibrosis bronchiectasis. This approval makes BRINSUPRI the first and only treatment for the condition in Japan, following its authorization in the United States and Europe. The approval is based on results from the Phase 3 ASPEN study, which showed that brensocatib reduced pulmonary exacerbations and was generally well tolerated.

    grafa.com•8/24/26•
    Bullish

    Japan approves the first treatment for a chronic lung disease that can damage lungs

    Insmed (Nasdaq: INSM) has announced that Japan's Ministry of Health, Labour and Welfare approved BRINSUPRI (brensocatib 25 mg) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients aged 12 and older. This makes BRINSUPRI the first and only approved treatment for NCFB in Japan, adding to its existing authorizations in the U.S. and Europe. The approval is based on positive results from the Phase 3 ASPEN study, which showed a significant reduction in pulmonary exacerbations and improved lung function compared to placebo.

    Stock Titan•8/24/26•
    Bullish

    Insmed Incorporated (INSM): Analyst Consensus Projects 59% Upside—A Biotech Powerhouse with Robust Growth Potential

    Insmed Incorporated (INSM) is an intriguing biotech stock with a current market cap of $27.47 billion, focusing on therapies for rare diseases. Analysts project a 59.06% upside with a target price of $200.05 and 23 unanimous buy ratings. Despite significant revenue growth of 296.10%, the company faces profitability challenges with negative net income, ROE, and free cash flow due to heavy R&D investments, yet it boasts a robust product pipeline and bullish technical indicators.

    DirectorsTalk Interviews•8/24/26•
    Bullish

    Frequently Asked Questions About INSM

    Does INSM pay dividends?
    Insmed Inc (INSM) does not currently pay a regular dividend.
    What is INSM's market cap?
    Insmed Inc (INSM) has a market capitalization of $25.89B with a current stock price of $121.82.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In